TOKYO--(BUSINESS WIRE)--PeptiDream Inc., a Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today the achievement of a milestone in one of the discovery programs in its alliance with US-based Bristol-Myers Squibb (NYSE:BMY). The milestone is the decision by Bristol-Myers Squibb to designate a Collaboration Compound as a candidate for exploratory clinical development, indicating that the compound has met certain pre-defined criteria and is now suitable for exploratory clinical development. The compound will now proceed to IND-enabling studies. Achievement of this milestone entitles PeptiDream to receive an undisclosed payment specified in the research collaboration and license agreement between PeptiDream and Bristol-Myers Squibb initiated October 15, 2010 and extended on October 15, 2012.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
